Wall Street’s top analyst calls

Wall Street’s top analyst calls
Post Author webadmin
2025-11-12

Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

  • KeyBanc upgraded AT&T (T) to Overweight from Sector Weight with a $30 price target. The recent share pullback has been driven by “overblown” wireless competition concerns, the firm tells investors in a research note.

  • KeyBanc upgraded Progyny (PGNY) to Overweight from Sector Weight with a $30 price target. The firm sees limited share downside from current levels and “several positive catalysts emerging” over the next 12 months.

  • Piper Sandler upgraded Floor & Decor (FND) to Overweight from Neutral with a price target of $80, up from $75. The firm cites the potential for comparable sales improvement by Q1 of 2026 and possible further acceleration in 2026 for the upgrade.

  • Guggenheim upgraded Grail (GRAL) to Buy from Neutral with a $100 price target. While the firm acknowledges that Galleri is “not a perfect test” and “may not be the holy grail of cancer detection,” Guggenheim says it is still the leading commercially available MCED test and sees it having a significant prospective data moat compared to competitors.

  • JPMorgan upgraded Outfront Media (OUT) to Overweight from Neutral with a price target of $25, up from $19. The out-of-home channel “stands out as the most resilient” traditional advertising market and momentum improved in Q3, the firm tells investors in a research note.

Top 5 Downgrades:

  • Raymond James downgraded Bath & Body Works (BBWI) to Market Perform from Outperform without a price target. The company’s growth will be below its long-term potential as improvements from better digital capabilities, product, and distribution will take time, the firm tells investors in a research note.

  • Wolfe Research downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target. The safety issue for nexiguran ziclumeran hinders the bull thesis, the firm tells investors in a research note.

  • Raymond James double downgraded Brighthouse Financial (BHF) to Market Perform from Strong Buy without a price target. The firm cites the announcement of its deal to be acquired by Aquarian for $70 per share for the downgrade.

  • Raymond James double downgraded Centerspace (CSR) to Market Perform from Strong Buy without a price target. The firm believes Centerspace’s portfolio is an attractive target for any number of potential buyers, but says that with the shares closing the valuation gap versus its multifamily peers “amid a backdrop of uncertain outcomes,” it feels stepping back to a neutral rating is appropriate on the recent rally.

  • Northland downgraded QuickLogic (QUIK) to Market Perform from Outperform with an unchanged price target of $5.95 after the company reported revenue in line with guidance and noted there is a $3M contract that may or may not hit in Q4 or Q1, which is resulting in a wide range of guidance.